Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Assets data on record, last reported at $3.3 billion in Q1 2026.

  • On a quarterly basis, Assets fell 0.88% to $3.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.3 billion, a 0.88% decrease, with the full-year FY2025 number at $3.0 billion, down 14.48% from a year prior.
  • Assets reached $3.3 billion in Q1 2026 per PCVX's latest filing, up from $3.0 billion in the prior quarter.
  • Over the last five years, Assets for PCVX hit a ceiling of $3.6 billion in Q3 2024 and a floor of $402.7 million in Q1 2022.
  • A 5-year average of $2.1 billion and a median of $2.1 billion in 2024 define the central range for Assets.
  • Peak YoY movement for Assets: soared 265.1% in 2023, then dropped 14.48% in 2025.
  • Tracing PCVX's Assets over 5 years: stood at $1.0 billion in 2022, then soared by 39.93% to $1.4 billion in 2023, then surged by 149.4% to $3.5 billion in 2024, then decreased by 14.48% to $3.0 billion in 2025, then grew by 11.51% to $3.3 billion in 2026.
  • Business Quant data shows Assets for PCVX at $3.3 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.2 billion in Q3 2025.